Varian, a Siemens Healthineers company, will showcase its ongoing commitment to embracing innovation and enhancing outcomes for cancer care teams and their patients at this year's 2024 European Society for Radiation Oncology (ESTRO) annual meeting, which will take place from May 3 to 7 in Glasgow, Scotland.
With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1. Radiotherapy is an integral part of therapeutic treatments for approximately 50% of the patients diagnosed with cancer, yet many countries have inadequate availability of radiotherapy treatment2. Varian is working in collaboration with healthcare providers to change that statistic by creating innovative and integrated solutions to help bring treatment options to those communities who need it most
Varian is working in collaboration with healthcare providers to change that statistic by creating innovative and integrated solutions to help bring treatment options to those communities who need it most
"As part of Siemens Healthineers, Varian is in a unique position to develop cutting-edge products and solutions that bridge the care gap globally," remarked Arthur Kaindl, Head of Varian. "By combining the expertise of the leading imaging and radiotherapy companies, we have the ability to achieve much more than any individual cancer care company by driving connection throughout the entire care continuum."
At the ESTRO meeting, Varian will present a range of solutions that will enhance the care continuum, including:
Varian is committed to generating evidence that can help improve patient outcomes and expand access to care. This commitment is evident through its efforts to elevate the standard of care, which will be showcased at ESTRO through numerous oral, panel, customer use cases, and poster presentations. These presentations, which include products such as Ethos and HyperSight imaging, will contribute to the growing body of clinical evidence and data across various treatment domains, further reinforcing Varian's dedication to enhancing patient care
These presentations, which include products such as Ethos and HyperSight imaging, will contribute to the growing body of clinical evidence and data across various treatment domains, further reinforcing Varian's dedication to enhancing patient care
VARIAN, HYPERSIGHT, ETHOS, HALCYON, EDGE, TRUEBEAM, ARIA CORE, and IDENTIFY are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat. & Tm. Off. MAGNETOM Free.Max, SOMATOM go.Sim, and SOMATOM go.Open Pro are trademarks of Siemens Healthcare GmbH registered U.S. Pat. & Tm. Off.
About VarianAt Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy, to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com
com
Press ContactKristin CoreyVarian Corporate Communications[email protected] 
1 Cancer Tomorrow | IARC - https://gco.iarc.who.int 2 M Abdel-Wahab, et al. JCO Global Oncol. 2021(7):827-842.
SOURCE Varian
Varian, a Siemens Healthineers company, will showcase its ongoing commitment to embracing innovation and enhancing outcomes for cancer care teams and ...
Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam ...

Source prnewswire